NCT06876701尚未招募1 期
The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Negative conversion rate of evaluable residual lesions (MRD)
研究概览
简要总结
Evaluation the efficacy and safety of the combination of injectable bevacizumab, low-intensity chemotherapy, and venula in the treatment of newly diagnosed CD19+mixed phenotype acute leukemia in adults
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients fully understand this study, voluntarily participate and sign an informed consent form (ICF);
- •Age: 18-75 years old (including boundary values of 18 and 75);
- •Clinically diagnosed adult Mixed Phenotype Acute Leukemia (WHO 2016 criteria) patients with CD19 positivity
排除标准
- •The subject's previous history of anti-tumor treatment meets one of the following conditions:
- •Individuals who have previously received bevacizumab
- •Individuals who have received CAR-T therapy or other gene modified cell therapies prior to screening;
- •Within 5 half lives of the first use of the investigational drug, having received anti-tumor treatment including surgery, chemotherapy, targeted therapy, or participating in other clinical trials and receiving clinical trial medication;
研究组 & 干预措施
Experimental group
Experimental
干预措施: Bevacizumab (Drug)
结局指标
主要结局
Negative conversion rate of evaluable residual lesions (MRD)
时间窗: 1 year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Bevacizumab and CHOP (A-CHOP) in Combination for Patients With Peripheral T-Cell or Natural Killer Cell NeoplasmsPER-015-08EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
Unknown
不适用
Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01912443Sun Yat-sen University600
招募中
不适用
A clinical study of Bevacizumab therapy in combination with chemotherapeutic drugs for children with recurrent gliomaJPRN-UMIN000005528Osaka University Graduate School of Medicine12
进行中（未招募）
2 期
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC PatientsNon-squamous NSCLCNCT05751187Shanghai Chest Hospital54
终止
1 期
CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)Acute Lymphoblastic LeukemiaNCT01195480University College, London29